ARCTURUS THERAPEUTICS HOLDINGS INC. Deferred Tax Assets, Operating Loss Carryforwards
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) had Deferred Tax Assets, Operating Loss Carryforwards of $38.57 million as of 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-03
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $38.57M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $25.41M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $19.15M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $47.87M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $38.57M 10-K · filed 2026-03-03 |
| 2024-12-31 | $25.41M 10-K · filed 2026-03-03 |
| 2023-12-31 | $19.15M 10-K · filed 2025-03-06 |
| 2022-12-31 | $47.87M 10-K · filed 2024-03-14 |
| 2021-12-31 | $69.76M 10-K · filed 2023-03-29 |
| 2020-12-31 | $33.90M 10-K · filed 2022-03-01 |
| 2019-12-31 | $15.08M 10-K · filed 2021-03-01 |
| 2018-12-31 | $8.40M 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |